Byeong Seon Jeong

This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Yeungnam University, Research Cooperation of Yeungnam University. Active years: 2016-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byeong Seon Jeong. Retrieved from https://idiyas.com/inventor/byeong-seon-jeong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 50.0

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

Research Cooperation of Yeungnam University

patent

Years Active: 2016-2018

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9889139 - Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject (2018-02-13),

2. 9802897 - Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component (2017-10-31),

3. 9505757 - Pharmaceutical composition comprising bicyclic pyridinol derivatives for preventing or treating diseases caused by angiogenesis (2016-11-29),

4. 9452159 - 6-aminopyridine-3-ol derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same as active ingredients for preventing or treating diseases caused by angiogenesis (2016-09-27),

Title: Innovations of Byeong Seon Jeong

Introduction

Byeong Seon Jeong is a notable inventor based in Daegu, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammatory bowel disease and cancer. With a total of four patents to his name, his work demonstrates a commitment to advancing medical science.

Latest Patents

One of his latest patents is a method of treating inflammatory bowel disease. This method involves administering a pharmaceutical composition that includes a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt as an active ingredient. This innovation has shown promise in inhibiting colitis in models of inflammatory bowel disease, making it a potential candidate for drug development aimed at prevention or treatment. Another significant patent involves an amidopyridinol derivative, which also includes a pharmaceutically acceptable salt. This derivative has demonstrated an antiangiogenic effect in a chorioallantoic membrane model, indicating its usefulness in preventing or treating diseases associated with angiogenesis. Additionally, it has shown a colitis-inhibitory effect, further supporting its application in inflammatory bowel diseases. The amidopyridinol derivative has also been found to inhibit angiogenesis and tumor growth in lung cancer models, showcasing its potential as an inhibitor of cancer growth and metastasis.

Career Highlights

Byeong Seon Jeong has worked with the Research Cooperation Foundation of Yeungnam University and the Research Cooperation of Yeungnam University. His career reflects a strong focus on research and development in the pharmaceutical sector, contributing to advancements in medical treatments.

Collaborations

He has collaborated with notable coworkers, including Jung Ae Kim and You Ra Kang. These partnerships have likely enhanced the scope and impact of his research efforts.

Conclusion

Byeong Seon Jeong's innovative work in pharmaceuticals highlights his dedication to improving medical treatments for serious conditions. His patents reflect a significant contribution to the fields of inflammatory bowel disease and cancer research.

Profile summary based on public USPTO records.